Suven Life Sciences Ltd's Q2FY17 standalone net profit rises 5.2% yoy to Rs.26.55 crore : Misses Estimates

India Infoline Research Team | November 24, 2016 17:08 IST

Suven Life Sciences Ltd Q2FY17

Standalone Results Q2FY17: (Rs. in crore)

Q2FY17 YoY (%)
Revenue 115.54 [1.2]
EDITDA 36.87 18.2
EBITDA Margin (%) 31.9 523
Net Profit (adjusted) 26.55 5.2
***EBITDA margin change is bps

Suven Life Science Ltd.’s standalone Q2FY17 result came in below Bloomberg estimates. Revenue came in 14.3% lower than the estimate of Rs 135 cr. Also, net profit was 13.8% lower than the estimated figure of Rs 31 cr.

Revenue for the quarter decreased 1.2% yoy to Rs 115.54 cr. This was led by 29% yoy dropped in services (DDDSS) segment.

EBITDA increased by 18.2% yoy to Rs 36.87 cr and EBITDA margins expanded by 523 bps to 31.9%. This was primarily driven by 34% yoy decline in cost of material consumed.

Net profit increased by 5.2% yoy to Rs 26.55 cr. This was led by higher effective tax rate of 32% (previously 19%).

Technical View:

Suven Life Sciences Ltd is currently trading at Rs. 179.4, up by 3.5 points or 1.99% from its previous closing of Rs. 175.9 on the BSE.
The scrip opened at Rs. 176.9 and has touched a high and low of Rs. 181 and Rs. 174.45 respectively. So far 343912(NSE+BSE) shares were traded on the counter. The stock is currently trading above its 200 DMA.

BSE 196.65 [1.50] ([0.76]%)
NSE 196.70 [1.80] ([0.91]%)

***Note: This is a NSE Chart



  • Save upto Rs.2.67 lakh with Pradhan Mantri Awas Yojana ...Know more
  • Now Save Rs.3150 on your Demat Account ...Click here
  • Now get IIFL Personal Loan in just 8* hours...APPLY NOW!
  • Get the most detailed result analysis on the web - Real Fast!
  • Actionable & Award-Winning Research on 500 Listed Indian Companies.